Connecting you to content on EBSCOhost

Works by Letrent, Stephen P.

Results: 3

1

A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer.

Published in:

Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 6, p. 1139, doi. 10.1007/s00280-009-0975-z

By:

Rixe, Olivier;
Franco, Sandra X.;
Yardley, Denise A.;
Johnston, Stephen R.;
Martin, Miguel;
Arun, Banu K.;
Letrent, Stephen P.;
Rugo, Hope S.

Publication type:

Article

2

Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.

Published in:

Cancer Chemotherapy & Pharmacology, 2008, v. 62, n. 1, p. 97, doi. 10.1007/s00280-007-0579-4

By:

Guo, Feng;
Letrent, Stephen P.;
Munster, Pamela;
Britten, Carolyn D.;
Gelmon, Karen;
Tolcher, Anthony W.;
Sharma, Amarnath

Publication type:

Article

3

Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors.

Published in:

Cancer Chemotherapy & Pharmacology, 2007, v. 60, n. 6, p. 799, doi. 10.1007/s00280-007-0427-6

By:

Feng Guo;
Letrent, Stephen P.;
Sharma, Amarnath

Publication type:

Article